A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).
Daniel Yick Chin Heng(University of Calgary), Toni K. Choueiri(Harvard University), Min‐Han Tan(National Cancer Centre Singapore), Lauren C. Harshman(Dana-Farber Cancer Institute), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Scott North, Sun Young Rha(Yonsei University), Ulka N. Vaishampayan(University of Michigan), Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Albiruni Ryan Abdul Razak(Roche (Switzerland)), Mary J. MacKenzie(Cancer Care Ontario), Neeraj Agarwal(University of Utah), Jae‐Lyun Lee(Ulsan College), Brian I. Rini(Vanderbilt University Medical Center)
Cited by 8
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k